PHIBRO ANIMAL HEALTH CORP (PAHC) earnings date
Feb 3, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q2 FY2027
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q1 FY2027 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q4 FY2026 | Wed, Aug 26, 2026 | after close | 57 | 8-K |
| Q3 FY2026 | Wed, May 6, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Wed, Feb 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Wed, Nov 5, 2025 | after close | 36 | 8-K |
| Q4 FY2025 | Wed, Aug 27, 2025 | after close | 58 | 8-K |
| Q3 FY2025 | Wed, May 7, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Wed, Feb 5, 2025 | after close | 36 | 8-K |
What they guided beta
| Q1 FY2027 | "EX-99.1 2 pahc-ex99d1.htm EX-99.1 Exhibit 99.1 For Immediate Release Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance TEANECK, N.J., November 4, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2026 and maintained its financial guidance for the year ending June 30, 2027. Highlights for the three months ended September 30, 2026 (compared to the three months ended September 30, 2025) - Net sales of $386.8 million," exhibit |
| Q1 FY2027 | "“When we set our fiscal 2027 outlook in August, we took a disciplined approach to virginiamycin sales in Brazil." exhibit |
| Q1 FY2027 | "Our fiscal 2027 guidance continues to assume no additional virginiamycin sales in Brazil for the remainder of the fiscal year, so any approval would represent potential upside.” “We generated positive cash flow in the first quarter, and we see a clear opportunity to do more, particularly in managing inventory." exhibit |
| Q1 FY2027 | "Given the timing of certain costs and the assumptions already built into our outlook, we are maintaining our fiscal 2027 financial guidance.” 1 QUARTERLY RESULTS Net sales Net sales of $386.8 million for the three months ended September 30, 2026 increased $22.9 million, or 6%, as compared to the three months ended September 30, 2025." exhibit |
| Q1 FY2027 | "Interest expense, net Interest expense, net of $11.3 million for the three months ended September 30, 2026 decreased by $0.8 million, as compared to the three months ended September 30, 2025, due to higher interest income attributable to interest received on IEEPA tariff recoveries and lower interest rates, partially offset by higher daily average borrowings on our revolving credit facility during the quarter." exhibit |
| Q4 FY2026 | "EX-99.1 2 pahc-20260826xex99d1.htm EX-99.1 Exhibit 99.1 For Immediate Release Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance TEANECK, N.J., August 26, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027. Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025) -" exhibit |
| Q4 FY2026 | "Production at the site is expected to cease during the summer of 2027." exhibit |
| Q4 FY2026 | "Manufacturing of products currently produced at Chicago Heights will be transferred to other Phibro-owned facilities and select third-party contract manufacturers. 1 COMMENTARY “Fiscal 2026 was a year of meaningful progress for Phibro,” said Dani Bendheim, President and Chief Executive Officer of Phibro Animal Health Corporation." exhibit |
| Q4 FY2026 | "Based on our fiscal 2027 outlook, nearly one out of every five dollars of Adjusted EBITDA can be traced to Phibro Forward initiatives realized since the start of the program." exhibit |
| Q4 FY2026 | "“Looking ahead to fiscal 2027, we expect continued growth across our businesses." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PAHC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PAHC
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/PAHC/"><img src="https://veritasdata.dev/embed/PAHC.svg" alt="PAHC earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/PAHC/)
Script
<script async src="https://veritasdata.dev/embed/PAHC.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PAHC"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.